BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Accumetrics, Inc. Release: 8500+ Patient Trial Validates Association Between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012


10/26/2012 7:50:16 AM

MIAMI--(BUSINESS WIRE)--Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced the presentation of the 1-year results from the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) registry at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting. Study findings indicate a significant association between platelet reactivity and 12-month stent thrombosis, myocardial infarction, and death. ADAPT-DES had previously demonstrated an approximately four times greater rate of stent thrombosis at 30-days in patients with high residual platelet reactivity (HRPR), as measured by Accumetrics’ VerifyNow P2Y12 Test. This association continued through follow-up, as patients with HRPR demonstrated a 2.5 times greater rate of stent thrombosis at 1-year. The VerifyNow P2Y12 Test and VerifyNow PRUTest are used to measure a patient’s platelet reactivity and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavix® and Effient®).

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES